

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) An isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1, consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID NO:3.

Claims 2-38. (cancelled).

Claim 39. (withdrawn-currently amended). A method for determining the presence of ~~an isolated a~~ a biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID NO:3 comprising:

(a) obtaining a sample from a patient;

(b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of said ~~isolated biopolymer selected from the group~~ consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID

NO:3 to mass spectrum profiles of peptides obtained and analyzed from said sample; and

(c) confirming the presence of said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID NO:3 in said sample displaying a peak profile of said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID NO:3 in said mass spectrum profile;

wherein the presence of said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID NO:3 is indicative of a link to Type II diabetes.

Claim 40. (withdrawn-currently amended). The method of claim 39, wherein [[the]] said sample is an unfractionated body fluid or a tissue sample.

Claim 41. (withdrawn). The method of claim 39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 42. (withdrawn). The method of claim 39, wherein said mass spectrometric analysis is selected from the group consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.

Claim 43. (withdrawn). The method of claim 39, wherein said patient is a human.

Claim 44. (withdrawn-currently amended). A kit for determining the presence of ~~an isolated~~ a biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID NO:3 comprising: (a) a peptide ~~selected from the group~~ consisting of SEQ ID NO:1, consisting of SEQ ID NO:2 [[and]] or consisting of SEQ ID NO:3 and (b) an antibody that binds to said peptide in a sample from a patient.

Claim 45. (withdrawn). The kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim 46. (withdrawn). The kit of claim 44, wherein said antibody is labeled.